Crossmark

Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres

Crossref DOI link: https://doi.org/10.1038/s41409-020-01086-9

Published Online: 2020-10-19

Published Print: 2021-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McCaughan, Georgia J. https://orcid.org/0000-0002-4838-9022
Verma, Anvita

Ling, Silvia https://orcid.org/0000-0001-9739-7101
Lavee, Orly

Moore, John J.

Bryant, Adam
License Information

Text and Data Mining valid from 2020-10-19

Version of Record valid from 2020-10-19
More Information

Article History

Received: 27 August 2020

Revised: 17 September 2020

Accepted: 7 October 2020

First Online: 19 October 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below